

OXFORD HAEMOPHILIA CENTRE

RPL £
Christmas Factor

Tel: Oxford GRO-C
and GRO-C Ext.....

Plasma Fractionation Laboratory*
Churchill Hospital,
Old Road, Headington,
Oxford,
OX3 7LJ.

Dr. W. d'A. Maycock,
Blood Products Laboratory,
The Lister Institute,
Elstree,
Herts.

7th August, 1973.

Dear Dr. Maycock,

I am very glad to see from your telephone message via Mrs. Sims on the 31st July that you have spoken to Professor Mollison about a meeting in the morning of the 15th November and that he approves of the idea. My suggestion would be that the people invited would be the same as on my enclosed list of possible members of a Working Party. I do not know if they will all realise that although factor IX has been prepared in England for almost as long as it has been prepared in France, the different administration whereby Professor Soulier has distributed the material has resulted in the very wide experience in France of the use of PPSB in conditions other than Christmas disease, whereas we acquired in this country a great depth of experience in the use of our old type concentrate for Christmas disease with almost no other controlled use. It is for this reason I think it is essential that the French experience be communicated and Professor Ménaché is in an excellent position to do this, not only because of her own involvement in this work from the beginning but also because she is the Chairman of the Task Force on the use of factor IX under the International Committee. I would suggest that I open this meeting by giving a brief account of this different approach, but at the same time say that it does not necessarily follow that experience with PPSB would be precisely the same as with preparations made by quite different methods. I think this introduction should last not more than ten minutes and we should then ask Professor Ménaché to discuss some of their actual experiences in detail, and if possible misconceptions about rationale for use. If she presents actual case histories this could take thirty minutes. The other participants who might be asked to contribute specifically are:-

1. ✓ Dr. Biggs on problems of assay and concentrates, and assessing results in patients.
2. ✓ Dr. Roger Williams on liver disease and the trial he has begun.
3. Dr. Stuart (Birmingham) on the trial he proposes.
4. Dr. Blank - a nominee from Edinburgh on its use in premature babies.
5. ✓ Dr. Ingram on reversal of Warfarin therapy.
6. ✓ Dr. Cash on present state of knowledge of possible hazards, as suggested by animal experimentation.

These contributors should be asked to limit their remarks to ten minutes to leave plenty of time for a general discussion to be aimed at listing the problems and outlining the means by which an answer should be sort. I would suggest that the Chairman

/should

*Headquarters: Blood Products Laboratory,
The Lister Institute, Elstree, Herts.

should be either Professor Mollison or yourself and that the objective should be make the maximum possible use of Professor Ménaché's presence in order that we can all clarify our minds about issues. I think this meeting should not concern itself with the problems of supply, other than that the people who are specifically proposing trials should be asked to give an estimate of what they think would be required in the country annually if their trial were to show the use of the concentrate to be beneficial.

Yours sincerely,

GRO-C

Ethel Bidwell.